Table 4.
Group number | Group designation | Targeted powder dose (mg) | Achieved average powder dose (mg) | % efficiency |
---|---|---|---|---|
1 | Placebo control | 40.0 | 33.0a | 82.5 |
37.1b | 92.8 | |||
3 | Low dose | 20.0 | 18.9a | 94.5 |
19.9b | 99.5 | |||
4 | High dose | 40.0 | 36.8a | 92.0 |
39.6b | 99.0 |
aCalculated using all values from the entire study including discharge weights obtained before implementation of a device wiping procedure to correct the adverse effect of device-related electrostatic charge on the analytical balance
bCalculated using values beginning April 8, 2011 (equivalent to study Day 10, 11, or 12 depending on the dog) after instituting a device wiping procedure to remove electrostatic charge and thus resulting in accurate and expected discharge weights